Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.
Bian H, Zheng ZH, Wei D, Wen A, Zhang Z, Lian JQ, Kang WZ, Hao CQ, Wang J, Xie RH, Dong K, Xia JL, Miao JL, Kang W, Li G, Zhang D, Zhang M, Sun XX, Ding L, Zhang K, Jia J, Ding J, Li Z, Jia Y, Liu LN, Zhang Z, Gao ZW, Du H, Yao N, Wang Q, Wang K, Geng JJ, Wang B, Guo T, Chen R, Zhu YM, Wang LJ, He Q, Yao RR, Shi Y, Yang XM, Zhou JS, Ma YN, Wang YT, Liang X, Huo F, Wang Z, Zhang Y, Yang X, Zhang Y, Gao LH, Wang L, Chen XC, Tang H, Liu SS, Wang QY, Chen ZN, Zhu P.
Bian H, et al. Among authors: wang yt, wang lj, wang l, wang k, wang j, wang z, wang qy, wang b, wang q.
Signal Transduct Target Ther. 2021 May 17;6(1):194. doi: 10.1038/s41392-021-00603-6.
Signal Transduct Target Ther. 2021.
PMID: 34001849
Free PMC article.
Clinical Trial.